Back to top
more

Glaukos (GKOS)

(Delayed Data from NYSE)

$119.82 USD

119.82
617,615

+2.17 (1.84%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $119.74 -0.08 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Glaukos (GKOS) Loses 14.3% Despite Narrower Loss in Q1

by Zacks Equity Research

Despite reporting first-quarter loss, Glaukos' (GKOS) results reflect rise in revenues.

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 30.00% and 4.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Glaukos (GKOS) Down 7.1% Since Last Earnings Report?

by Zacks Equity Research

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Glaukos (GKOS) Stock Right Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

    Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Glaukos' (GKOS) fourth-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

    Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Glaukos (GKOS) delivered earnings and revenue surprises of 93.75% and 0.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Glaukos (GKOS) Up 24.3% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Glaukos (GKOS) Beats Estimates on Narrower-than-Expected Loss (revised)

    by Zacks Equity Research

    Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.

    Glaukos (GKOS) Gains 11.8% Despite Reporting Loss in Q3

    by Zacks Equity Research

    Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

    Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Glaukos (GKOS) delivered earnings and revenue surprises of 80.43% and 19.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: Glaukos (GKOS) Q3 Earnings Expected to Decline

    by Zacks Equity Research

    Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Glaukos (GKOS) Down 1.6% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Glaukos (GKOS) Loses 17.1% Despite Q2 Earnings & Revenues Beat

    by Zacks Equity Research

    Glaukos' (GKOS) second-quarter results reflect fall in revenues partially mitigated by contribution from Avedro buyout.

    Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Glaukos (GKOS) delivered earnings and revenue surprises of 21.79% and 55.92%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

    Glaukos (GKOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

    by Zacks Equity Research

    Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Here's Why You Should Retain Glaukos in Your Portfolio Now

    by Zacks Equity Research

    Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.

    Glaukos (GKOS) Up 13.8% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates

    by Zacks Equity Research

    Glaukos (GKOS) witnessed a contraction in gross margin but year-over-year revenue surge in Q1.

    Glaukos (GKOS) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Glaukos (GKOS) delivered earnings and revenue surprises of -25.71% and -0.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

    Glaukos (GKOS) Down 45.8% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Glaukos (GKOS) fourth-quarter results benefit from revenue growth. However, rise in operating expenses remains a concern.

    What's in the Offing for LabCorp's (LH) Earnings in Q4?

    by Zacks Equity Research

    With near-term visibility seeming bleak at the moment, we anticipate PAMA to once again dent LabCorp's (LH) fourth-quarter top line.

    What's in the Cards for DaVita (DVA) This Earnings Season?

    by Zacks Equity Research

    DaVita (DVA) expects to have gained from calcimimetics in the fourth quarter.